Extensions of indication throughout the drug product lifecycle: a quantitative analysis-Reference-Cited by-同舟云学术

Extensions of indication throughout the drug product lifecycle: a quantitative analysis

Published:2016-02 Issue:2 Volume:21 Page:348-355
ISSN:1359-6446
Container-title:Drug Discovery Today
language:en
Short-container-title:Drug Discovery Today

Author:

Langedijk Joris^ORCID,Whitehead Christopher J.,Slijkerman Diederick S.,Leufkens Hubert G.M.,Schutjens Marie-Hélène D.B.,Mantel-Teeuwisse Aukje K.

Publisher

Elsevier BV

Subject

Drug Discovery,Pharmacology

Reference29 articles.

1. Intellectual property. Balancing innovation and access: patent challenges tip the scales;Higgins;Science,2009

2. The influence of market exclusivity on drug availability and medical innovations;Glover;AAPS J.,2007

3. The impact of incremental innovation in biopharmaceuticals: drug utilisation in original and supplemental indications;Berndt;Pharmacoeconomics,2006

4. Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use (Art. 10, paragraph 5). Available at: http://eur-lex.europa.eu/.

5. Recent trends in brand-name and generic drug competition;Grabowski;J. Med. Econ.,2014

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparing supplemental indications for cancer drugs approved in the US and EU;European Journal of Cancer;2024-09

2. Drug Repurposing of Generic Drugs: Challenges and the Potential Role for Government;Applied Health Economics and Health Policy;2023-07-03

3. Off-label despite high-level evidence: a clinical practice review of commonly used off-patent cancer medicines;ESMO Open;2023-02

4. How to balance valuable innovation with affordable access to medicines in Belgium?;Frontiers in Pharmacology;2022-09-16

5. Diminishing clinical impact for post-approval cancer clinical trials: A retrospective cohort study;PLOS ONE;2022-09-12